Joanna Metzner-Sadurski, MD
Hematology & Oncology · Greenwood, SCNPI 1801807011
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,478 of the $17,612 with a category attached, or 82.2%. 35 manufacturers reported payments, led by AstraZeneca at 46.3% of the total. 2025 is the largest year on record at $6,632, more than ten times the $531 reported in 2019.
Across 82 payments — averaging $214.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Karyopharm Therapeutics Inc.$3K
- Beigene USA, Inc.$2K
- Bayer$1K
- Beigene, Ltd.$525
- Pharmacosmos Therapeutics Inc.$478
- plus $2K from 29 others
Across 34 payments — averaging $77.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Consulting fees$14,47882%
- Speaking & faculty fees$4503%
- Travel & lodging$8885%
- Food & beverage$1,3007%
- Education$4973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $8,149 |
| Karyopharm Therapeutics Inc. | 4 | $2,895 |
| Beigene USA, Inc. | 4 | $2,216 |
| Bayer | 1 | $1,283 |
| Beigene, Ltd. | 1 | $525 |
| Pharmacosmos Therapeutics Inc. | 1 | $478 |
| Novocure GmbH | 1 | $250 |
| Lilly USA, LLC | 5 | $246 |
| Daiichi Sankyo Inc. | 2 | $223 |
| Johnson & Johnson | 5 | $159 |
| Novartis | 6 | $153 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Astellas Pharma US Inc | 2 | $107 |
| Incyte Corporation | 1 | $103 |
| AbbVie | 1 | $84 |
| Merck | 5 | $84 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Ipsen Biopharmaceuticals, Inc | 3 | $59 |
| Amgen | 3 | $45 |
| Seagen Inc. | 2 | $36 |
| Tesaro, Inc. | 1 | $34 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| KARL Storz Endoscopy-america | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $15 |
| Gilead | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Kyowa Kirin, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$3,060
- XPOVIO$2,855
- BRUKINSA$2,700
- Vitrakvi$1,283
- IMFINZI$925
- Truqap$525
- LYNPARZA$525
- Monoferric$478
- NURTEC ODT$122
How this compares
$17,612 in reported general payments places this provider in the 80th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 65 | $756,988 |
| PomalystPomalidomide | 40 | $673,474 |
| ImbruvicaIbrutinib | 43 | $640,136 |
| CabometyxCabozantinib S-Malate | 19 | $489,709 |
| CalquenceAcalabrutinib Maleate | 24 | $274,597 |
| ScemblixAsciminib Hydrochloride | 11 | $237,116 |
| TagrissoOsimertinib Mesylate | 12 | $188,460 |
| VerzenioAbemaciclib | 11 | $169,956 |
| IbrancePalbociclib | 14 | $158,332 |
| BrukinsaZanubrutinib | 12 | $125,314 |
| EliquisApixaban | 106 | $80,580 |
| Abiraterone Acetate | 41 | $78,113 |
| Imatinib Mesylate | 31 | $4,205 |
| Lansoprazole | 16 | $4,115 |
| Letrozole | 217 | $3,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $65 | $673,47440 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $77 | $640,13643 claims |
| AstraZenecaCalquence, Tagrisso | $8,149 | $463,05736 claims |
| NovartisScemblix | $153 | $237,11611 claims |
| Lilly USA, LLCVerzenio | $246 | $169,95611 claims |
| Beigene USA, Inc.Brukinsa | $2,216 | $125,31412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenwood
- Ruiling YuanGreenwood$8K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.